Insider Selling: Urogen Pharma (NASDAQ:URGN) Insider Sells $142,560.60 in Stock

Posted by George Bondi on Jun 12th, 2026

Urogen Pharma (NASDAQ:URGN – Get Free Report) insider Mark Schoenberg sold 5,222 shares of the firm’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $27.30, for a total transaction of $142,560.60. Following the completion of the transaction, the insider directly owned 139,763 shares in the company, valued at approximately $3,815,529.90. This represents a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Urogen Pharma Stock Up 5.4%

URGN stock opened at $29.50 on Friday. Urogen Pharma has a 12 month low of $6.92 and a 12 month high of $32.37. The firm has a market cap of $1.44 billion, a P/E ratio of -10.73 and a beta of 1.59. The company’s 50-day moving average price is $25.51 and its two-hundred day moving average price is $22.82.

Urogen Pharma (NASDAQ:URGN – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.01. The firm had revenue of $50.96 million during the quarter, compared to the consensus estimate of $44.83 million. Equities analysts predict that Urogen Pharma will post -0.98 EPS for the current year.

Institutional Investors Weigh In On Urogen Pharma

Several hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. boosted its position in Urogen Pharma by 27.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after buying an additional 486 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Urogen Pharma by 7.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after buying an additional 1,653 shares during the period. Main Street Financial Solutions LLC boosted its position in Urogen Pharma by 8.2% during the 2nd quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock worth $356,000 after buying an additional 1,968 shares during the period. Barclays PLC boosted its position in Urogen Pharma by 3.8% during the 4th quarter. Barclays PLC now owns 57,744 shares of the company’s stock worth $1,352,000 after buying an additional 2,125 shares during the period. Finally, Osaic Holdings Inc. boosted its position in Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after buying an additional 3,070 shares during the period. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on URGN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a report on Monday, April 20th. Oppenheimer reaffirmed an “outperform” rating on shares of Urogen Pharma in a report on Tuesday, June 2nd. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price target on shares of Urogen Pharma in a report on Wednesday, June 3rd. LADENBURG THALM/SH SH began coverage on shares of Urogen Pharma in a report on Monday, May 11th. They set a “buy” rating and a $43.00 price target on the stock. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $33.00 price target on shares of Urogen Pharma in a report on Tuesday, March 31st. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $36.67.

View Our Latest Stock Analysis on Urogen Pharma

About Urogen Pharma

(Get Free Report)

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.